Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Cohort A (before or during chemotherapy):
- Adults aged 18 or older who are about to start cisplatin-based chemotherapy, either on its own or combined with other drugs that are not known to cause nerve damage
- People whose blood test results are healthy enough to safely receive chemotherapy
Cohort B (after chemotherapy):
- Adults aged 18 or older who have already been diagnosed with nerve damage caused by cisplatin treatment
- People whose last cisplatin dose was at least 3 months before joining the study
- People who previously took part in Cohort A may be eligible for Cohort B if nerve damage symptoms are still present 3 months after finishing cisplatin treatment
Who may not be able to join:
Cohort A:
- People who already had nerve damage before starting chemotherapy
- People with a family history of inherited nerve conditions
- People whose doctor has determined that cisplatin treatment is not safe for them
- People whose chemotherapy plan combines cisplatin with another drug also known to cause nerve damage
- People who have a cardiac (heart) or spinal stimulating device implanted
- People who are pregnant or breastfeeding
- People who are not able to independently complete questionnaires about their symptoms
- People with other health conditions that the treating doctor believes would make participation unsafe
- People who are unlikely to be able to follow the study requirements
Cohort B:
- People who already had nerve damage before their cisplatin treatment
- People with a family history of inherited nerve conditions
- People whose cisplatin treatment was combined with another drug also known to cause nerve damage
- People who have a cardiac (heart) or spinal stimulating device implanted
- People who are pregnant or breastfeeding
- People who are not able to independently complete questionnaires about their symptoms
- People with other health conditions that the treating doctor believes would make participation unsafe
- People who are unlikely to be able to follow the study requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ka-Wai Ho, MD, Beth Israel Deaconess Medical Center
Phone: 617-667-1665
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Presence of change in Nerve Excitability in comparison to baseline nerve excitability.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.